A summary of approvals, recalls, warnings and alerts digested by ACP Internist from the Food and Drug Administration's alerts.
Albiglutide (Tanzeum) to treat type 2 diabetes in adults, along with diet and exercise. ... treat type 1 diabetes or diabetic ketoacidosis, or as a first-line therapy.
It was approved under the FDA's priority review program. Linagliptin (Tradjenta) tablets to treat type 2 diabetes, along with diet and exercise. ... It should not be used to treat people with type 1 diabetes or diabetic ketoacidosis.
This regulatory update covers warnings to lower zolpidem doses in women and approvals for a new drug to improve blood glucose control in adults with type 2 diabetes. ... control in adults with type 2 diabetes, along with diet and exercise.
An ever-changing knowledge base without clear consensus makes diabetes management especially challenging. ... The typical strategy for reducing diabetes complications—good glucose control—seems not to apply in bone health.
The Closing the Gap project began by collecting data on the practices' diabetes-related procedures and patients. ... The overwhelming response led to its reprinting for phase II of the Diabetes Initiative.
well as lost more weight and experienced larger reductions in diabetes medication use. ... American Diabetes Association.Economic costs of diabetes in the U.S. in 2017.
The question is whether and when the process is worthwhile for patients with relatively uncomplicated type 2 diabetes. ... Another issue that crosses socioeconomic boundaries, particularly among patients with diabetes, is depression.
Including expanded online diabetes management offerings and MKSAP updates. ACP's Diabetes Portal. ... The ACP Diabetes Portal, a site that was developed to assist the entire clinical care team in ensuring high-quality care of patients with diabetes, has
The algorithm calls for home monitoring in patients with target organ disease or diabetes who have a pressure of over 130/80 and other patients at 140/90.